Daily Dosing of PDE5 Inhibitors: Where Does It Fit In?

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2013 Jun 19

PMID 23775467

Citations 2

Authors

King Chien Joe Lee

Gerald B Brock

Affiliations

Soon will be listed here.

Abstract

To provide a critical contemporary review of daily PDE5-inhibitor (PDE5-I) use in urological and nonurological conditions. PDE5-Is can be taken up to once a day. However, at present only tadalafil is approved for use in both erectile dysfunction (ED) and benign prostate hyperplasia (BPH) with lower urinary tract symptoms (LUTS). Evolving research in penile rehabilitation, Peyronie's disease, male infertility, pulmonary arterial hypertension, muscular dystrophy and Raynaud's phenomenon shows these therapeutic areas may also benefit from PDE5i therapy. This review examines the role of chronic PDE5 inhibition in ED, BPH-LUTS and other therapeutic targets which may shape our clinical practice in the years to come.

Citing Articles

Diagnostic and Therapeutic Workup of Erectile Dysfunction: Results From a Delphi Consensus of Andrology Experts.

Isidori A, Giammusso B, Corona G, Verze P Sex Med. 2019; 7(3):292-302.

PMID: 31196744 PMC: 6728771. DOI: 10.1016/j.esxm.2019.04.001.

Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Lee M, Sharifi R Drugs Aging. 2018; 35(3):175-187.

PMID: 29464656 DOI: 10.1007/s40266-018-0528-4.

References

Herrick A . Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am. 2008; 34(1):89-114. DOI: 10.1016/j.rdc.2007.11.006. View

Chung E, Brock G . Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013; 10 Suppl 1:102-11. DOI: 10.1111/j.1743-6109.2012.03005.x. View

Corbin J, Francis S, Webb D . Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002; 60(2 Suppl 2):4-11. DOI: 10.1016/s0090-4295(02)01686-2. View

Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, Gonzalez-Cadavid N . Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006; 3(1):84-94. DOI: 10.1111/j.1743-6109.2005.00197.x. View

Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A . EAU guidelines on penile curvature. Eur Urol. 2012; 62(3):543-52. DOI: 10.1016/j.eururo.2012.05.040. View

Shenoy P, Kumar S, Jha L, Choudhary S, Singh U, Misra R . Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010; 49(12):2420-8. DOI: 10.1093/rheumatology/keq291. View

Galie N, Brundage B, Ghofrani H, Oudiz R, Simonneau G, Safdar Z . Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22):2894-903. DOI: 10.1161/CIRCULATIONAHA.108.839274. View

Shlobin O, Brown A, Weir N, Ahmad S, Lemma M, Nathan S . Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. Lung. 2012; 190(5):573-8. DOI: 10.1007/s00408-012-9408-6. View

De Young L, Domes T, Lim K, Carson J, Brock G . Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol. 2008; 54(1):213-20. DOI: 10.1016/j.eururo.2008.02.034. View

10.

Montorsi F, Brock G, Lee J, Shapiro J, van Poppel H, Graefen M . Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008; 54(4):924-31. DOI: 10.1016/j.eururo.2008.06.083. View

11.

Schiopu E, Hsu V, Impens A, Rothman J, McCloskey D, Wilson J . Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol. 2009; 36(10):2264-8. DOI: 10.3899/jrheum.090270. View

12.

. FDA approves oral therapy for erectile dysfunction. Am J Health Syst Pharm. 1998; 55(10):981, 984. DOI: 10.1093/ajhp/55.10.981a. View

13.

Gonzalez-Cadavid N, Rajfer J . Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010; 7(4):215-21. DOI: 10.1038/nrurol.2010.24. View

14.

Vasconcelos J, Figueiredo R, Nascimento F, Damiao R, da Silva E . The natural history of penile length after radical prostatectomy: a long-term prospective study. Urology. 2012; 80(6):1293-6. DOI: 10.1016/j.urology.2012.07.060. View

15.

McMahon C . Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2006; 1(3):292-300. DOI: 10.1111/j.1743-6109.04042.x. View

16.

Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J . Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2007; 101(2):203-10. DOI: 10.1111/j.1464-410X.2007.07223.x. View

17.

Porst H, Kim E, Casabe A, Mirone V, Secrest R, Xu L . Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60(5):1105-13. DOI: 10.1016/j.eururo.2011.08.005. View

18.

Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati K, Montague D . Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res. 2005; 18(1):77-81. DOI: 10.1038/sj.ijir.3901380. View

19.

Dimitriadis F, Tsambalas S, Tsounapi P, Kawamura H, Vlachopoulou E, Haliasos N . Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU Int. 2010; 106(8):1181-5. DOI: 10.1111/j.1464-410X.2010.09243.x. View

20.

Egerdie R, Auerbach S, Roehrborn C, Costa P, Garza M, Esler A . Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2011; 9(1):271-81. DOI: 10.1111/j.1743-6109.2011.02504.x. View